Catalyst Pharmaceuticals (CPRX) Cost of Revenue (2019 - 2026)

Catalyst Pharmaceuticals (CPRX) has 8 years of Cost of Revenue data on file, last reported at $14.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 19.18% year-over-year to $14.5 million; the trailing twelve-month figure through Mar 2026 stood at $83.8 million (up 12.91% YoY), and the FY2025 full-year result was $87.3 million, up 26.74% from the prior year.
• Cost of Revenue for Q1 2026 stood at $14.5 million, down from $26.1 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $26.1 million in Q4 2025 and bottomed at $5.9 million in Q1 2022.
• The 5-year median for Cost of Revenue is $14.5 million (2026), against an average of $15.1 million.
• The widest annual swing landed in 2022, when Cost of Revenue soared 82.02%; it then declined 19.18% in 2026.
• A 5-year view of Cost of Revenue shows it stood at $11.2 million in 2022, then soared by 41.21% to $15.8 million in 2023, then soared by 36.9% to $21.6 million in 2024, then grew by 20.47% to $26.1 million in 2025, then sank by 44.48% to $14.5 million in 2026.
• The last three Cost of Revenue figures came in at $14.5 million (Q1 2026), $26.1 million (Q4 2025), and $22.7 million (Q3 2025), per Business Quant data.

Peer Comparison